Summary
We examined the effects of 60 minα-hANP infusion (24 ng/min/kg) on glomerular filtration rate (GFR), renal blood flow (RBF), cardiac index (CI) and blood pressure (BP) in 8 patients with chronic renal failure (CRF) with GFR ranging from 18 to 80 ml/min/1.73 m2 and in 8 control (C) subjects with normal renal function. Basal plasma levels of ANP and cGMP were elevated in CRF (ANP: 60.6±9.1 vs 13.6±1.9 pmol/l,p<0.05; cGMP: 14.3±2.9 vs 6.6±1.1 pmol/ml,p<0.05). During ANP infusion, peak levels of cGMP were higher in CRF than in C (27.5±3.2 vs. 17.3±1.3 pmol/ml,p<0.05). During ANP infusion, GFR increased in CRF by 70.7±4.2% from 34.5±6.8 to 57.4±9.9 ml/min/1.73m2 (p<0.001) as compared to 16.2±1.4% in C (p<0.001 vs CRF). RBF increased in CRF by 43.6±6.4% and in C by 3.1±1.2% (p<0.01). Basal urinary sodium excretion (UNaV) was slightly lower in CRF than in C but rose to the same level in both groups during ANP infusion. In CRF, as opposed to C, UNaV remained elevated above baseline after the end of the infusion. The effect of ANP on fractional sodium excretion (FENa), however, was more pronounced in C. Basal FENa was higher in CRF (12.8±2.5% vs 2.4±1.5% in C,p<0.001), FENa remained elevated at 180% over baseline in C sixty minutes after cessation of ANP infusion, while it had returned to baseline in CRF. During ANP infusion, CI increased in CRF after 30 min from 2.91±0.08 to 3.12±0.091/min/m2 (p<0.001) and in C from 3.20±0.11 to 3.39±0.13 l/min/m2 (p< 0.05). Mean arterial BP was higher in CRF and its decrease was greater than in C (21.1±2.7% vs 9.1±1.0%,p<0.001). In patients with CRF GFR, RPF, and CI remained significantly elevated and BP was still significantly decreased 60 min after ANP infusion. Total peripheral vascular resistance (TPR) was elevated in CRF and declined during ANP infusion in both CRF and C. The decline of TPR was sustained and more pronounced in CRF than in C. Renal vascular resistance (RVR) was high in CRF and dropped by nearly 50% during ANP infusion, whereas only a moderate decline in RVR during ANP application was observed in C. Thus, exogenous ANP had greater and prolonged effects on systemic hemodynamics and renal function in CRF than in C. They may be due to higher levels of ANP following ANP infusion and appear to be mediated by a more sustained formation of the second messenger cGMP.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- ANP:
-
atrial natriuretic peptide
- CRF:
-
chronic renal failure;
- GFR:
-
glomerular filtration rate
- FF:
-
filtration fraction
- ERPF:
-
effective renal plasma flow
- ERBF:
-
effective renal blood flow
- BP:
-
blood pressure
- MAP:
-
mean arterial blood pressure
- HR:
-
heart rate
- SV:
-
stroke volume
- CO:
-
cardiac output
- CI:
-
cardiac index
- TPR:
-
total peripheral resistance
- RVR:
-
renal vascular resistance
- UNaV:
-
urinary sodium excretion
- FENa :
-
fractional sodium excretion
- PRA:
-
plasma renin activity
- ECFV:
-
extracellular fluid volume
- PAH:
-
paminohippuric acid
References
Borenstein HB, Cupples WA, Sonnenberg H, Veress AT (1983) The effect of natriuretic atrial extract on renal hemodynamics and urinary excretion in anesthetized rats. J Physiol [Lond] 334:133–140
Burnier M, Mooser V, Wauters JP, Marder HK, De Vane P, Nussberger J, Waeber B, Brunner HR (1989) Bolus injection of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndrome. J Cardiovasc Pharmacol 13:682–690
Canella G, Rodella A, Brunori G, Gaggiotti M, Sandrini M, Maiorca R (1987) Plasma concentrations of atrial natriuretic peptide in relation to body fluid status in chronic uremia. Nephrol Dial Transplant 2:158–160
Cody RJ, Atlas SA, Laragh JH (1986) Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 78:1362–1374
Czekalski S, Michel C, Dussaule JC, Touraine P, Mignon F, Ardaillou R (1988) Atrial natriuretic peptide and adaptation of sodium urinary excretion in patients with chronic renal failure. Clin Sci 75:243–249
Earle DP, Berliner RW (1946) A simplified clinical procedure for measurement of glomerular filtration rate and renal plasma flow. Proc Soc Exp Biol Med 62:262–266
Epstein M (1989) Atrial natriuretic factor in patients with liver disease. Am J Nephrol 9:89–100
Epstein M, Norsk P, Loutzenhiser R (1989) Effects of water immersion on atrial natriuretic peptide release in humans. Am J Nephrol 9:1–24
Espiner EA, Nicholls MG, Yandle TG (1986) Studies on the secretion, metabolism and action of atrial natriuretic peptide in man. J Hypertens 4 (Suppl 2):S85-S91
Gerbes AL, Arendt RM, Paumgartner G (1987) Atrial natriuretic factor. Possible implications in liver disease. J Hepatol 5:123–132
Gerbes AL, Kollenda MC, Vollmar AM, Reichen J, Vakil N, Scarborough RM (1991) Altered density of glomerular binding sites for atrial natriuretic factor in bile duct-ligated rats with ascites. Hepatol 13:562–566
Gerbes AL, Vollmar AM (1990) Degradation and clearance of atrial natriuretic factors (ANF). Life Sci 47:1173–1180
Glänzer K, Prüßing B, Kramer HJ (1982) Hemodynamic and hormonal responses to 8-Arginine-Vasopressin in healthy man: effects of indomethacin. Klin Wochenschr 60:1234–1239
Haller BGD, Züst HJ, Shaw S, Gnädinger MP, Uehlinger DE, Weidmann P (1987) Effects of posture and aging on circulating atrial natriuretic peptide levels in man. J Hypertens 5:551–556
Hammond TG, Yusufi ANK, Knox FG, Dousa TP (1985) Administration of atrial natriuretic factor inhibits proximal Na-coupled solute transport. J Clin Invest 75:1983–1989
Harris PJ, Thomas D, Morgan TO (1987) Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature (London) 326:697–698
Hollister AS, Tanaka I, Imada T (1986) Sodium loading and posture modulate human atrial natriuretic factor plasma levels. Hypertension 8 (Suppl II):II-106–II-111
Katsube N, Schwartz D, Needleman P (1985) Release of atriopeptin in the rat by vasoconstrictors or water immersion correlates with changes in right atrial pressure. Biochem Biophys Res Commun 133:937–944
Kollenda MC, Vollmar AM, McEnroe GA, Gerbes AL (1990) Dehydration increases the density of C receptors for ANF in rat glomerular membranes. Am J Physiol 258:R1084-R1088
Lang RE, Tholken H, Ganten D, Luft FC, Ruskoaho H, Unger T (1985) Atrial natriuretic factor: A circulating hormone stimulated by volume loading. Nature (London) 314:264–266
Maack TM, Kleinert HD (1986) Renal and cardiovascular effects of atrial natriuretic factor. Biochem Pharmacol 35:2057–2064
Meyer-Lehnert H, Till C, Predel HG, Kramer HJ (1989) Beeinflußt Nifedipin die Sekretion von atrialem natriuretischem Peptid während Wasserimmersion? In: Kaufmann W, Wambach M (Eds) Endocrinology of the heart. Springer, Berlin, p 236–239
Michel H, Meyer-Lehnert H, Bäcker A, Stelkens H, Kramer HJ (1990) Regulation of atrial natriuretic peptide receptors in glomeruli during chronic salt loading. Kidney Int 38:73–79
Nakao K, Sugawara A, Morii N (1986) The pharmacokinetics of a-human atrial natriuretic polypeptide in healthy subjects. Eur J Clin Pharmacol 31:101–103
Nakaoka H, Imataka K, Amano M, Fuji J, Ishibashi M, Yamaji T (1985) Plasma levels of atrial natriuretic factor in patients with congestive heart failure. N Engl J Med 313:1027–1036
Nishiuchi T, Saito H, Yamasaki Y, Shiro S (1986) Radioimmunoassay for atrial natriuretic peptide: method and results in normal subjects and patients with various diseases. Clin Chim Acta 159:45–57
Ogawa K, Smith AI, Hodsman GP, Jackson B, Woodcock EA, Johnston CI (1987) Plasma atrial natriuretic peptide: concentrations and circulating forms in normal man and patients with chronic renal failure. Clin Exp Pharmacol Physiol 14:95–102
Ortola FV, Ballermann B, Brenner BM (1988) Endogenous ANP augments fractional excretion of Pi, Ca, and Na in rats with reduced renal mass. Am J Physiol 255:F1091-F1097
Predel HG, Kipnowski J, Meyer-Lehnert H, Kramer HJ (1988) Human atrial natriuretic peptide in non-dialyzed patients with chronic renal failure. Clin Nephrol 31:150–151
Predel HG, Schulte-Vels O, Sorger M, Glänzer K, Geller C, Kramer HJ (1990) Atrial natriuretic peptide in patients with diabetes mellitus type I. Effects on systemic and renal hemodynamics and renal excretory function. Am J Hyperten 3:674–681
Proctor KG, Bealer SL (1986) Selective antagonism of hormone-induced vasoconstriction by atrial natriuretic factor in the rat microcirculation. Circ Res 61:42–49
Rascher W, Tulassay T, Lang RE (1985) Atrial natriuretic peptide in plasma of volume overloaded children with chronic renal failure. Lancet 2:303–305
Richards AM, Nicholls MG, Ikram H (1985) Renal hemodynamic and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers. Lancet II:545–549
Richards AM, Tonolo G, Montrosi P, Finlayson J, Fraser R, Inglis G, Towrie A, Morton JJ (1988) Low dose infusion of 26- and 28-amino acid human atrial natriuretic peptides in normal man. J Clin Endocrin Metab 66:465–472
Saxenhofer H, Gnädinger MP, Weidmann P, Shaw S, Schohn D, Hess C, Uehlinger DE, Jahn H (1987) Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure. Kidney Int 32:554–561
Schmidt RW, Bourgoignie JJ, Bricker NS (1966) On the adaptation in sodium excretion in chronic uremia. The effects of “proportional reduction” of sodium intake. J Clin Invest 53:1736–1741
Slatopolski E, Elkan IO, Weerts C, Bricker NS (1968) Studies on the characteristics of the control system governing sodium excretion in uremic man. J Clin Invest 47:521–530
Solomon LR, Atherton JC, Bobinski H, Hillier V, Green R (1988) Effect of low dose infusion of atrial natriuretic peptide on renal function in man. Clin Sci 75:403–410
Sonnenberg H, Honrath U, Chong CK, Wilson DR (1986) Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol 250:F963-F966
Steiner AL, Parker CW, Kipnis DM (1972) Radioimmunoassay for cyclic nucleotides. J Biol Chem 247:1106–1110
Suda S, Weidmann P, Saxenhofer H, Cottier C, Shaw SG, Ferner C (1988) Atrial natriuretic factor in mild to moderate chronic renal failure. Hypertension 11:483–490
Tonolo G, McMillan M, Polonia J, Pazzola A, Montorsi P, Soro A, Glorioso N, Richards MA (1988) Plasma clearance and effects ofα-hANP infused in patients with end-stage renal failure. Am J Physiol 254:F895-F899
Vetter W, Vetter H, Siegenthaler W (1973) Radioimmunoassay for aldosterone without chromatography: 2. Determination of plasma aldosterone. Acta Enocrinol 74:558–567
Walker RG, Swainson CP, Yandle TG, Nicholls MG, Espiner EA (1987) Exaggerated responsiveness of immunoreactive atrial natriuretic peptide to saline infusion in chronic renal failure. Clin Sci 72:19–24
Weidmann P, Hellmüller B, Uehlinger DE (1986) Plasma levels and cardiovascular, endocrine, and excretory effects of atrial natriuretic peptide during different sodium intakes in man. J Clin Endocrinol Metab 62:1027–1036
Yamaji T, Ishibashi M, Takaku F (1985) Atrial natriuretic factor in human blood. J Clin Invest 76:1705–1709
Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH (1986) Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 38:1827–1833
Author information
Authors and Affiliations
Additional information
Dedicated to Prof. Dr. med. F. Krück on the occasion of his 70th birthday
Rights and permissions
About this article
Cite this article
Meyer-Lehnert, H., Bayer, T., Predel, H.G. et al. Effects of atrial natriuretic peptide on systemic and renal hemodynamics and renal excretory function in patients with chronic renal failure. Klin Wochenschr 69, 895–903 (1991). https://doi.org/10.1007/BF01649565
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01649565